All In Biotech

NDA 019193 · Methapharm

Provocholine

Methacholine Chloride · Inhalation

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Jun 6, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1986

Oct 31, 1986

Approved uses

2

Original approval plus efficacy supplements

Registered trials

67

12 Phase 3, 2 recruiting

FAERS reports

73

36 serious, 4 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SEVERE BRONCHOCONSTRICTION WARNING: SEVERE BRONCHOCONSTRICTION Severe bronchoconstriction can result from Provocholine administration (including the lowest dose). The use of Provocholine is contraindicated in pediatric and adult patients with baseline FEV1 < 60% predicted or adults with FEV1 < 1.5 L. Because of the potential for severe bronchoconstriction, the use of Provocholine in patients with clinically apparent asthma or wheezing is not recommended [ see Warnings and Precautions (5.1) ]. Emergency equipment and medication should be immediately available to treat acute respiratory distress. If severe bronchoconstriction occurs, reverse immediately with a rapid-acting inhaled bronchodilator agent (β-agonist) [ see Warnings and Precautions (5.1) ]. If baseline spirometry is not performed or is measured inaccurately, the initial FEV1 may be underestimated. In this situation,...

What it is approved for

From the label in effect Jul 15, 2026.

Provocholine, used in a methacholine challenge test, is indicated for the diagnosis of bronchial airway hyperreactivity in adults and pediatric patients five years of age and older who do not have clinically apparent asthma. Provocholine, a cholinergic agonist used in a methacholine challenge test, is indicated for the diagnosis of bronchial airway hyperreactivity in adults and pediatric patients five years of age and older who do not have clinically apparent asthma (1)

Mechanism: Methacholine chloride is a cholinergic agonist. Bronchial smooth muscle contains significant parasympathetic (cholinergic) innervation. Methacholine chloride agonizes the muscarinic receptors which eventually induce bronchoconstriction.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 8, 2019 Supplement 21 · Efficacy LabelLetter
  • Oct 31, 1986 Original approval · Type 1 - New Molecular Entity · priority review
2 products under this application
  • PROVOCHOLINE · METHACHOLINE CHLORIDE 1600MG/VIAL · FOR SOLUTION, INHALATION · Discontinued
  • PROVOCHOLINE · METHACHOLINE CHLORIDE 100MG/VIAL · FOR SOLUTION, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Methacholine Chloride" as an intervention, any sponsor and status, largest first.

All 67 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • chest discomfort8
  • dyspnoea7
  • fatigue7
  • headache6
  • dizziness5
  • drug ineffective5
  • urticaria5
  • angioedema4
  • anxiety4
  • asthma4
  • benign prostatic hyperplasia4
  • pain4

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20073
20081
20094
20102
20117
20123
20131
20153
20166
20173
20181
20197
20208
20213
20227
20234
20245
20252
20262

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Provocholine (Methacholine Chloride) · HCPCS J7674

2024 spending

$76K

Beneficiaries

1,905

1,914 claims

Per beneficiary

$40

2024 ASP limit $1.25 per unit

View as table
YearSpending
2020$68,767
2021$82,585
2022$54,574
2023$53,164
2024$75,743

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 20 on PubMed

Sponsor: Methapharm

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.